202 related articles for article (PubMed ID: 29575198)
1. Down-regulation of microRNA-19b in hormone receptor-positive/HER2-negative breast cancer.
Maleki E; Ghaedi K; Shahanipoor K; Karimi Kurdistani Z
APMIS; 2018 Apr; 126(4):303-308. PubMed ID: 29575198
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of miR-9 in benign and malignant breast tumors.
Hasanzadeh A; Mesrian Tanha H; Ghaedi K; Madani M
Mol Cell Probes; 2016 Oct; 30(5):279-284. PubMed ID: 27725294
[TBL] [Abstract][Full Text] [Related]
3. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
4. Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer.
Kalinina T; Kononchuk V; Alekseenok E; Obukhova D; Sidorov S; Strunkin D; Gulyaeva L
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33923732
[TBL] [Abstract][Full Text] [Related]
5. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G
Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of a five-microRNA signature in breast carcinoma as a promising biomarker for diagnosis.
Bitaraf A; Babashah S; Garshasbi M
J Clin Lab Anal; 2020 Feb; 34(2):e23063. PubMed ID: 31595567
[TBL] [Abstract][Full Text] [Related]
7. Functional SNP in stem of mir-146a affects Her2 status and breast cancer survival.
Meshkat M; Tanha HM; Naeini MM; Ghaedi K; Sanati MH; Meshkat M; Bagheri F
Cancer Biomark; 2016 Jul; 17(2):213-22. PubMed ID: 27434289
[TBL] [Abstract][Full Text] [Related]
8. PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer.
Li RK; Gao J; Guo LH; Huang GQ; Luo WH
Cancer Gene Ther; 2017 Jul; 24(7):309-315. PubMed ID: 28731027
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
10. miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.
Nassar FJ; El Sabban M; Zgheib NK; Tfayli A; Boulos F; Jabbour M; El Saghir NS; Talhouk R; Bazarbachi A; Calin GA; Nasr R
PLoS One; 2014; 9(9):e107566. PubMed ID: 25232827
[TBL] [Abstract][Full Text] [Related]
11. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
12. miR-125a-5p expression is associated with the age of breast cancer patients.
He H; Xu F; Huang W; Luo SY; Lin YT; Zhang GH; Du Q; Duan RH
Genet Mol Res; 2015 Dec; 14(4):17927-33. PubMed ID: 26782438
[TBL] [Abstract][Full Text] [Related]
13. Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels.
Petrovic N; Davidovic R; Jovanovic-Cupic S; Krajnovic M; Lukic S; Petrovic M; Roganovic J
Mol Diagn Ther; 2016 Dec; 20(6):603-615. PubMed ID: 27488105
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker.
Erbes T; Hirschfeld M; Rücker G; Jaeger M; Boas J; Iborra S; Mayer S; Gitsch G; Stickeler E
BMC Cancer; 2015 Mar; 15():193. PubMed ID: 25886191
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA and LncRNA Expression Profiles in Human Estrogen Receptor Positive Breast Cancer.
Shao X; Huang P; Shi L; Lei L; Cao W; Chen Z; Wang X; Zheng Y
Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775882
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
17. microRNA-214 enhances the invasion ability of breast cancer cells by targeting p53.
Wang F; Lv P; Liu X; Zhu M; Qiu X
Int J Mol Med; 2015 May; 35(5):1395-402. PubMed ID: 25738546
[TBL] [Abstract][Full Text] [Related]
18. Her-2 expression regulated by downregulation of miR-9 and which affects chemotherapeutic effect in breast cancer.
Sun G; Sun L; Liu Y; Xing H; Wang K
Cancer Gene Ther; 2017 May; 24(5):194-202. PubMed ID: 28361910
[TBL] [Abstract][Full Text] [Related]
19. The role of upregulated miR-375 expression in breast cancer: An in vitro and in silico study.
Tang W; Li GS; Li JD; Pan WY; Shi Q; Xiong DD; Mo CH; Zeng JJ; Chen G; Feng ZB; Huang SN; Rong MH
Pathol Res Pract; 2020 Jan; 216(1):152754. PubMed ID: 31787478
[TBL] [Abstract][Full Text] [Related]
20. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC.
Petrovic N; Sami A; Martinovic J; Zaric M; Nakashidze I; Lukic S; Jovanovic-Cupic S
Pathol Res Pract; 2017 Oct; 213(10):1264-1270. PubMed ID: 28935174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
